Personalized navigation may boost cancer screening in high-risk communities

NCT ID NCT07676383

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests whether giving people a personalized report about their cancer risk and screening options helps them complete recommended cancer tests. Adults aged 45 to 74 who are at high risk for lung, breast, colorectal, upper gastrointestinal, or liver cancer are invited to take part. Some receive a tailored navigation report with step-by-step guidance, while others get general health education or no active promotion. The goal is to see if personalized support increases screening participation and improves early detection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

precision navigation intervention (personalized report and staff explanation)

What this could lead to

If effective, this approach could increase cancer screening rates in high-risk communities, leading to earlier detection and better outcomes.

What could go wrong

This is a behavioral intervention study, not a drug trial. Results may vary by community and may not generalize beyond the specific program in China.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colorectal cancer colorectal neoplasm digestive system neoplasm gastroesophageal cancer liver cancer Liver Neoplasms lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••